PDE4D and breast carcinoma: Analysis of a large dataset comprising 2283 patients with primary, ER+ breast cancer treated with endocrine therapy revealed that high mRNA expression of PDE4D is associated with significantly worse relapse-free survival (RFS) also in early-stage disease (Supplementary Fig. 4c).